摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

阿朴吗啡 | 41372-20-7

中文名称
阿朴吗啡
中文别名
(R)-(-)-阿朴吗啡盐酸盐半水;(R)-5,6,6a,7-四氢-6-甲基-4H-二苯并[de,g]喹啉-10,11-二醇;盐酸阿扑吗啡
英文名称
6-methyl-6aβ-aporphane-10,11-diol; hydrochloride
英文别名
6-Methyl-6aβ-aporphan-10,11-diol; Hydrochlorid;6-Methyl-6aβ-aporphan-10,11-diol; Hydrochlorid-Hydrat;Apomorphine hydrochloride hemihydrate;(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrate;hydrochloride
阿朴吗啡化学式
CAS
41372-20-7
化学式
4C17H17NO2*4ClH*3H2O
mdl
——
分子量
1269.2
InChiKey
DQQCJDBYNZMPOA-FFXKMJQXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    285-287 °C(lit.)
  • 比旋光度:
    -48 º (c=1, H2O)
  • 溶解度:
    在水中的溶解度~10 mg/mL,澄清,黄绿色
  • 稳定性/保质期:

计算性质

  • 辛醇/水分配系数(LogP):
    2.45
  • 重原子数:
    22
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    44.7
  • 氢给体数:
    4
  • 氢受体数:
    4

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
母乳喂养期间使用总结:目前没有关于在哺乳期间使用阿扑吗啡的信息。如果母亲需要阿扑吗啡,这并不是停止哺乳的理由。然而,阿扑吗啡在动物中抑制催乳素的释放,可能会干扰乳汁生成的建立。在哺乳新生儿或早产儿时,可能更倾向于使用其他药物。 ◉ 对哺乳婴儿的影响:截至修订日期,没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响:截至修订日期,没有找到相关的已发布信息。
◉ Summary of Use during Lactation:No information is available on the use of apomorphine during breastfeeding. If apomorphine is required by the mother, it is not a reason to discontinue breastfeeding. However, apomorphine inhibits prolactin release in animals and might interfere with establishment of lactation. An alternate drug may be preferred, especially while nursing a newborn or preterm infant. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S36
  • 危险类别码:
    R22
  • WGK Germany:
    3
  • 海关编码:
    2933997000
  • 危险品运输编号:
    UN 2811 6.1/PG 3
  • 储存条件:
    本品应密封避光保存。

SDS

SDS:7d4b76142c134df5469e168fda6cf417
查看

Section 1. Chemical Product and Company Identification
Apomorphine Hydrochloride, hemihydrate Catalog
Common Name/
Number(s).
Trade Name
CAS#
Apomorphine Hydrochloride, hemihydrate

Section 3. Hazards Identification
Hazardous in case of ingestion, of inhalation (lung sensitizer). Slightly hazardous in case of skin contact (irritant,
Potential Acute Health
sensitizer), of eye contact (irritant).
Effects
CARCINOGENIC EFFECTS: Not available.
Potential Chronic Health
MUTAGENIC EFFECTS: Mutagenic for bacteria and/or yeast.
Effects
TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available.
The substance may be toxic to kidneys, gastrointestinal tract, central nervous system (CNS).
Repeated or prolonged exposure to the substance can produce target organs damage.

Section 4. First Aid Measures
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least
Eye Contact
15 minutes. Cold water may be used. Get medical attention if irritation occurs.
Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.
Skin Contact
Cold water may be used.
Not available.
Serious Skin Contact
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
Inhalation
medical attention.
Not available.
Serious Inhalation
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
Ingestion
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Not available.
Serious Ingestion

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Not available.
Flash Points
Not available.
Flammable Limits
These products are carbon oxides (CO, CO2), nitrogen oxides (NO, NO2...), halogenated compounds.
Products of Combustion
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Non-flammable in presence of shocks.
Various Substances
Slightly explosive in presence of open flames and sparks.
Explosion Hazards in
Non-explosive in presence of shocks.
Presence of Various
Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
and Instructions
As with most organic solids, fire is possible at elevated temperatures
Special Remarks on
Fire Hazards
Fine dust dispersed in air in sufficient concentrations, and in the presences of an ignition source is a potential dust
Special Remarks on
explosion hazard.
Explosion Hazards
Apomorphine Hydrochloride, hemihydrate

Section 6. Accidental Release Measures
Use appropriate tools to put the spilled solid in a convenient waste disposal container. If necessary: Neutralize the
Small Spill
residue with a dilute solution of sodium carbonate. Finish cleaning by spreading water on the contaminated
surface and dispose of according to local and regional authority requirements.
Use a shovel to put the material into a convenient waste disposal container. Neutralize the residue with a dilute
Large Spill
solution of sodium carbonate. Finish cleaning by spreading water on the contaminated surface and allow to
evacuate through the sanitary system.

Section 7. Handling and Storage
Keep away from heat. Keep away from sources of ignition. Do not breathe dust. Wear suitable protective clothing.
Precautions
In case of insufficient ventilation, wear suitable respiratory equipment. If you feel unwell, seek medical attention and
show the label when possible. Keep away from incompatibles such as oxidizing agents, alkalis.
Keep container tightly closed. Keep container in a cool, well-ventilated area. Sensitive to light. Store in
Storage
light-resistant containers. Air Sensitive

Section 8. Exposure Controls/Personal Protection
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
Engineering Controls
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to
avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
of a Large Spill
handling this product.
Not available.
Exposure Limits

Section 9. Physical and Chemical Properties
Solid. (Crystalline powder.) Odorless.
Physical state and O dor
appearance
Not available.
Taste
312.8 g/mole
Molecular Weight
White. Off-white.
Color
4 - 5[Acidic.]
pH (1% soln/water)
Not available.
Boiling Point
195°C (383°F)
Melting Point
Not available.
Critical Temperature
Not available.
Specific Gravity
Not applicable.
Vapor Pressure
Not available.
Vapor Density
Not available.
Volatility
Not available.
Odor Threshold
Not available.
Water/Oil Dist. Coeff.
Not available.
Ionicity (in Water)
See solubility in water.
Dispersion Properties
Soluble in cold water.
Solubility
Slightly soluble in diethyl ether.
Solubility in water: 20 g/l
Insoluble in chloroform.
Apomorphine Hydrochloride, hemihydrate

Section 10. Stability and Reactivity Data
The product is stable.
Stability
Not available.
Instability Temperature
Conditions of Instability Excess heat, incompatible materials, dust generation
Incompatibility with various Reactive with oxidizing agents, alkalis.
substances
Not available.
Corrosivity
Air and light sensitive.
Special Remarks on
Incompatible with iodides, tannin, iron salts
Reactivity
Not available.
Special Remarks on
Corrosivity
Will not occur.
Polymerization

Section 11. Toxicological Information
Inhalation. Ingestion.
Routes of Entry
Acute oral toxicity (LD50): 300 mg/kg [Mouse].
Toxicity to Animals
Chronic Effects on Humans MUTAGENIC EFFECTS: Mutagenic for bacteria and/or yeast.
May cause damage to the following organs: kidneys, gastrointestinal tract, central nervous system (CNS).
Other Toxic Effects on Hazardous in case of ingestion, of inhalation (lung sensitizer).
Humans Slightly hazardous in case of skin contact (irritant, sensitizer).
Not available.
Special Remarks on
Toxicity to Animals
May affect genetic material (mutagenic).
Special Remarks on
Chronic Effects on Humans May cause adverse reproductive effects based on animal test data
Special Remarks on other Acute Potential Health Effects:
Toxic Effects on Humans Skin: Skin contact may cause redness, irritation and sensitization. Absorption through skin (e.g. by subcutaneous
injection will produce systemic and central nervous symtpoms similar that of ingestion or inhalation.
Eyes: May cause redness, and irritation.
Inhalation: Inhalation of dust may cause sensitization, asthma, and respiratory tract irritation. Inhalation of dust may
also cause nausea, and vomiting, and may affect behavior/central nervous system (symptoms similar to that of
ingestion)
Ingestion: May be harmful if swallowed. Causes gastrointestinal tract irritation with abdominal pain, nausa, vomiting
and diarrhea. May affect behavior/central nervous system and cause stimulation and depression of the central
nervous system. Symptoms may include restlessness, euphoria, drowsiness or sleepiness, yawning, somnolence,
dizziness, sedation, cognitive impairment, personality change, lightheadedness, tremors, confusion, halllucinations,
coma/unconsciousness. Other symptoms may include pin point or dilated pupils, respiratory depression, postural
hypotension, sore throat, increased cough, rhihitis, flushing, taste disorder, sweating, circulatory failure, death. It may
also affect the kidneys.
Chronic Potential Health Effects:
Ingestion or Skin Absorption/Subcutaneous injection: Prolonged or repeated ingestion or exposure by subcutaneous
injection may have systemic and nervous system symptoms similar to that of acute ingestion or inhalation and affect
the kidneys, adrenal gland and cause loss of appetite/weight loss.

Section 12. Ecological Information
Not available.
Ecotoxicity
Not available.
BOD5 and COD
Products of Biodegradation Possibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
Apomorphine Hydrochloride, hemihydrate
The products of degradation are more toxic than the product itself.
Toxicity of the Products
of Biodegradation
Not available.
Special Remarks on the
Products of Biodegradation

Section 13. Disposal Considerations
Waste Disposal Waste must be disposed of in accordance with federal, state and local environmental control
regulations.

Section 14. Transport Information
Not a DOT controlled material (United States).
DO T Cl assi fi cati on
Not applicable.
Identification
Not applicable.
Special Provisions for
Transport
DO T (Pi ctograms)

Section 15. Other Regulatory Information and Pictograms
No products were found.
Federal and State
Regulations
California prop. 65: This product contains the following ingredients for which the State of California has found to
California
cause cancer which would require a warning under the statute: No products were found.
Proposition 65
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has found to
cause birth defects which would require a warning under the statute: No products were found.
Not available.
Other Regulations
WHMIS (Canada) Not controlled under WHMIS (Canada).
Other Classifications
R20/22- Harmful by inhalation and if S24- Avoid contact with skin.
DSCL (EEC)
swallowed. S36/37- Wear suitable protective clothing and
R42/43- May cause sensitization by gloves.
inhalation and skin contact. S46- If swallowed, seek medical advice
immediately and show this container or label.
Health Hazard
HMIS (U.S.A.) 2 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
2 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection E
WHMIS (Canada)
(Pictograms)
Apomorphine Hydrochloride, hemihydrate
DSCL (Europe)
(Pictograms)
TDG(Canada)
(Pictograms)
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or equivalent.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质

本品为白色细结晶性粉末,熔点在285-287℃之间。1克粉末能溶于50毫升中、17毫升80℃的热中以及50毫升乙醇中;极微溶于氯仿及醚。其1:300溶液的pH值为4.8。暴露在光线下和空气中会分解并变成绿色。

用途

本品是一种催吐药物。

生产方法

该药物由吗啡经消除、重排、成盐而制得。具体步骤如下:

  1. 吗啡加入磷酸中,浴加热,确保内温不超过50℃。
  2. 搅拌至完全溶解后,冷却并置于吸收罐内。
  3. 通入氯化氢气体直至反应液的重量达到吗啡量的2.5倍。
  4. 将其移入反应罐内,继续通入氯化氢气体,并加热至124-126℃,保温反应3小时。
  5. 反应完成后,将反应液放入冰中冷却至20℃以下,搅拌下慢慢加入碳酸直至胶状物完全析出。
  6. 分取胶状物并将其加入浓盐酸中,在沸中溶解得到的盐酸盐,再加入亚硫酸钠溶液中。
  7. 二氯乙烷-异丙醇混合溶媒提取两次。
  8. 提取液于搅拌下加入浓盐酸,析出粗品。
  9. 将所得粗品用浓盐酸浸泡、热蒸馏溶解、加活性炭脱色、真空干燥等步骤,最终得到成品。

文献信息

  • [EN] HYDANTOIN DERIVATIVE<br/>[FR] DÉRIVÉ D'HYDANTOÏNE
    申请人:ONO PHARMACEUTICAL CO
    公开号:WO2021043245A1
    公开(公告)日:2021-03-11
    A compound represented by general formula (I-a) : has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.
    一种由一般化学式(I-a)表示的化合物具有强大的DDR1抑制活性,可作为DDR1相关疾病的治疗药物,例如癌症、肾脏疾病、心血管疾病、中枢神经系统疾病或纤维化病。
  • AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION
    申请人:Toray Industries, Inc.
    公开号:EP3777858A1
    公开(公告)日:2021-02-17
    An object of the present invention is to provide an agent for inhibiting a rise in intraneuronal calcium concentration. The present invention provides an agent for inhibiting a rise in intraneuronal calcium concentration, comprising a cyclic amine derivative represented by the following chemical formula or a pharmacologically acceptable salt thereof as an active ingredient.
    本发明的目的是提供一种抑制神经元内浓度升高的药剂。本发明提供了一种抑制神经元内浓度升高的制剂,其活性成分包括由以下化学式代表的环胺衍生物或其药理学上可接受的盐。
  • Effervescent formulations comprising apomorphine
    申请人:Larsen Finn
    公开号:US20060141032A1
    公开(公告)日:2006-06-29
    An effervescent formulation comprising apomorphine, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising apomorphine wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the apomorphine. The formulation is used for the treatment of male and female sexual dysfunction.
    一种含有阿朴吗啡的泡腾制剂,最好是含有酸性物质、碱性物质和溶性隔离剂的多层泡腾微球。一种含有阿扑吗啡的泡腾制剂,其中的多层泡腾微球溶解于后几乎立即起泡,形成阿扑吗啡的溶液或均匀分散体。该制剂用于治疗男性和女性性功能障碍。
  • CRYSTALLINE FORM OF S-APOMORPHINE
    申请人:Aclipse One, Inc.
    公开号:EP3793980A1
    公开(公告)日:2021-03-24
  • EP3838246A1
    申请人:——
    公开号:EP3838246A1
    公开(公告)日:2021-06-23
查看更多